Adaptimmune Therapeutics PLC
NASDAQ:ADAP
Adaptimmune Therapeutics PLC
Selling, General & Administrative
Adaptimmune Therapeutics PLC
Selling, General & Administrative Peer Comparison
Competitive Selling, General & Administrative Analysis
Latest Figures & CAGR of Competitors
Company | Selling, General & Administrative | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Adaptimmune Therapeutics PLC
NASDAQ:ADAP
|
Selling, General & Administrative
-$64.5m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
|
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
Selling, General & Administrative
-$53.7m
|
CAGR 3-Years
-261%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Autolus Therapeutics PLC
NASDAQ:AUTL
|
Selling, General & Administrative
-$54.9m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Selling, General & Administrative
-$62.2m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-45%
|
CAGR 10-Years
N/A
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Selling, General & Administrative
-£144.5m
|
CAGR 3-Years
-47%
|
CAGR 5-Years
-38%
|
CAGR 10-Years
N/A
|
|
Genus PLC
LSE:GNS
|
Selling, General & Administrative
-£7.6m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-9%
|
See Also
What is Adaptimmune Therapeutics PLC's Selling, General & Administrative?
Selling, General & Administrative
-64.5m
USD
Based on the financial report for Dec 31, 2023, Adaptimmune Therapeutics PLC's Selling, General & Administrative amounts to -64.5m USD.
What is Adaptimmune Therapeutics PLC's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 5Y
-8%
Over the last year, the Selling, General & Administrative growth was -6%. The average annual Selling, General & Administrative growth rates for Adaptimmune Therapeutics PLC have been -12% over the past three years , -8% over the past five years .